부신기능저하증에 대한 현재의 치료 전략은 주로 하이드로코르티손, 프레드니솔론, 덱사메타손과 같은 기존의 글루코코르티코이드 대체요법에 의존하고 있으며, 이는 부신기능부전의 기본 치료제로 작용하고 있습니다. 이러한 약물은 부신 기능 부전의 위험을 줄이고 관련 증상을 효과적으로 관리하기 위해 필수적인 코티솔을 보충하는 중요한 역할을 합니다. 또한 특히 원발성 부신 기능 부전 환자에서는 전해질 균형과 혈압 조절을 회복하기 위해 플루드로코르티손을 이용한 미네랄 코르티코이드 보충 요법이 처방되기도 합니다.
1일 1회 투여하는 하이드로코르티손 제제나 서방형 프레드니솔론 정제와 같은 글루코코르티코이드의 장시간 작용형 제제는 기존 제제 대비 약동학이 개선되어 증상 조절을 개선할 수 있는 가능성이 있습니다. 개선될 수 있습니다. 응급 치료 프로토콜에는 비경구 하이드로코르티손의 즉각적인 투여(bolus injection)와 환자의 상태를 안정화시키기 위한 유지 투여가 포함됩니다. 현재 급성 부신피질호흡곤란증 관리에 대한 업계 표준은 응급용 항염증 글루코코르티코이드인 Solu-Cortef Act-O-VIAL입니다.
전통적인 글루코코르티코이드 대체요법이 여전히 기본이지만, 약물전달, 보조 요법, 디지털 건강 솔루션의 발전으로 부신 기능 부전을 예방하고 관리하기 위한 보다 종합적인 환자 중심의 접근법이 형성되고 있습니다. 이러한 혁신은 부신기능부전 환자의 삶의 질과 장기적인 결과를 개선하기 위한 노력을 반영하고 있습니다. 향후 수년간 부신기능부전증 시장의 성장 전망에서 알 수 있듯이, 지속적인 연구와 활동을 통해 더 효과적인 치료와 궁극적으로 이 어려운 부신기능부전증을 치료할 수 있을 것으로 기대됩니다.
부신 위기의 주요 7 시장(미국, 독일, 스페인, 이탈리아, 프랑스, 영국, 일본)에 대해 조사분석했으며, 각 지역의 시장 규모, 현재 치료법, 미충족 요구, 신약 등의 정보를 제공하고 있습니다.
DelveInsight's comprehensive report titled "Adrenal Crisis Market Insights, Epidemiology, and Market Forecast 2034" offers a detailed analysis of Adrenal Crisis. The report presents historical and projected epidemiological data covering Total Diagnosed Prevalent Cases of Adrenal Insufficiency, Type-specific Diagnosed Prevalent Cases of Adrenal Insufficiency, Total Diagnosed Prevalent Cases of Adrenal Crisis, Gender-specific Diagnosed Prevalent Cases of Adrenal Crisis, and Treatable Cases of Adrenal Crisis. In addition to epidemiology, the market report encompasses various aspects related to the patient population. These aspects include the diagnosis process, prescription patterns, physician perspectives, market accessibility, treatment options, and prospective developments in the market across seven major markets: the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, spanning from 2020-2034.
The report analyzes the existing treatment practices and unmet medical requirements in Adrenal Crisis. It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions. This valuable information enables stakeholders to make well-informed decisions regarding product development and strategic planning for the market.
Adrenal Crisis Treatment Market
Adrenal Crisis, also referred to as Addisonian crisis is a life-threatening condition characterized by insufficient production of cortisol and occasionally aldosterone, a condition commonly termed Adrenal Insufficiency. Patients may experience dizziness, weakness, sweating, abdominal pain, dehydration, low blood pressure, nausea, vomiting, or even loss of consciousness.
Adrenal insufficiency can be categorized into primary, secondary, and tertiary causes. Primary adrenal insufficiency arises from underlying issues affecting the adrenal gland directly. Secondary adrenal insufficiency occurs due to diminished levels of adrenocorticotrophic hormone (ACTH) released from the pituitary gland. Tertiary adrenal insufficiency arises from decreased levels of corticotrophin-releasing hormone (CRH) released from the hypothalamus.
Adrenal Crisis Diagnosis and Treatment Algorithm
Diagnosis of Adrenal Crisis may be difficult due to the presence of non-specific symptoms, Gastroenteritis and the Syndrome of Inappropriate Secretion of Antidiuretic Hormones (SIADH) are the most frequently reported misdiagnosis in patients with adrenal insufficiency (AI). However, the following tests can help properly diagnose adrenal crisis. Such tests are Adrenocorticotropic hormone (ACTH) blood tests, Blood tests, Cortisol tests, and Potassium and Sodium blood tests.
The definitive treatment of Adrenal Crisis includes the administration of GCs, specifically hydrocortisone. In adults, the recommended treatment regimen includes administering an initial dose of 100 mg of hydrocortisone through intravenous or intramuscular (IV/IM) bolus injection.
The epidemiology section on the Adrenal Crisis market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.
This section also presents the data with relevant tables and graphs, offering a clear and concise view of the prevalence of Adrenal Crisis. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.
Key Findings
In addressing adrenal crisis, current treatment strategies primarily rely on established glucocorticoid replacement therapies like hydrocortisone, prednisolone, and dexamethasone, which serve as foundational treatments for adrenal insufficiency. These medications play a crucial role in providing essential cortisol replacement to mitigate the risk of adrenal crises and effectively manage associated symptoms. Additionally, mineralocorticoid replacement therapy, typically with fludrocortisone, may be prescribed to restore electrolyte balance and blood pressure regulation, especially in individuals with primary adrenal insufficiency.
Innovations in drug delivery systems have emerged to enhance treatment efficacy and patient convenience. Long-acting formulations of glucocorticoids, such as once-daily hydrocortisone preparations and modified-release prednisolone tablets, offer improved pharmacokinetics and potentially better symptom control compared to traditional regimens. Emergency treatment protocols include the immediate administration of parenteral hydrocortisone via bolus injection, followed by maintenance doses to stabilize the patient's condition. The current industry standard for managing acute adrenal crises is Solu-Cortef Act-O-VIAL, an emergency anti-inflammatory glucocorticoid.
While traditional glucocorticoid replacement therapies remain fundamental, ongoing advancements in drug delivery, adjunctive therapies, and digital health solutions are shaping a more comprehensive and patient-centric approach to preventing and managing adrenal crises. These innovations reflect a commitment to improving the quality of life and long-term outcomes for individuals with adrenal insufficiency. Looking ahead, with continued research and dedication, there is optimism for even more effective treatments and, ultimately, a cure for this challenging condition, as evidenced by projected market growth in the Adrenal Crisis market in the coming years.
Marketed Adrenal Crisis Drugs
SOLU-CORTEF: Pfizer Inc.
Solu-Cortef Act-O-VIAL is a brand name for hydrocortisone sodium succinate, a medication commonly used in the treatment of adrenal crisis. It is available in a powder form for reconstitution and administration via intravenous (IV) or intramuscular (IM) injection. Solu-Cortef Act-O-VIAL is a vital component of emergency treatment protocols for adrenal crisis, providing immediate cortisol replacement to stabilize patients at risk of life-threatening complications. Its rapid action and availability in a convenient vial format make it a preferred choice for healthcare providers managing adrenal insufficiency emergencies.
Emerging Adrenal Crisis Drugs
The Adrenal Crisis market is expected to experience gradual changes, mainly due to the limited availability of emerging therapies in this area. Key market players are Antares Pharmaceuticals and others, which are actively working on novel treatments
ATRS-1902: Antares Pharmaceuticals
A noteworthy candidate in the pipeline is ATRS-1902 by Antares Pharma, which was in the Phase III stage of development. This therapy, designed for use during the adrenal crisis, received FDA Fast Track designation in January 2022. Positive results from a Phase I study for ATRS-1902, focusing on adrenal crisis rescue, were announced by the company in the same month. The study demonstrated that ATRS-1902 (100 mg) delivered a comparable pharmacokinetic profile and was safe and well-tolerated.
It is essential to highlight that Antares Pharma, the company developing ATRS-1902, underwent an acquisition by Halozyme. As of the latest available information, no further updates on the development of ATRS-1902 have been provided, however, the drug is on the company's pipeline.
Adrenal Crisis Market Segmentation
DelveInsight's 'Adrenal Crisis Market Insights, Epidemiology, and Market Forecast - 2034' report provides a detailed outlook of the current and future Adrenal Crisis market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.
Adrenal Crisis Market Size by Countries
The Adrenal Crisis market size is assessed separately for various countries, including the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. In 2023, the United States held a significant share of the overall 7MM (Seven Major Markets) Adrenal Crisis market, primarily attributed to the country's higher prevalence of the condition and cost of the available treatments. This dominance is projected to persist, especially with the potential early introduction of new products.
Adrenal Crisis Market Size by Therapies
The current landscape for emerging therapies addressing Adrenal Crisis reveals a notable scarcity, emphasizing the urgent unmet need for advancements in this area. The absence of approved therapies highlights a critical gap, and the development and introduction of novel treatments are crucial to address this deficiency.
Adrenal Crisis Market Size by Therapies is categorized into current and emerging markets for the study period 2020-2034. One of the emerging drugs anticipated to launch during the forecast period is ATRS-1902 under the developmental pipeline of Antares Pharma.
This section focuses on the sales uptake of potential Adrenal Crisis drugs that have recently been launched or are anticipated to be launched in the Adrenal Crisis market between 2020 and 2034. It estimates the market penetration of Adrenal Crisis drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the Adrenal Crisis market.
Adrenal Crisis Market Access and Reimbursement
DelveInsight's 'Adrenal Crisis Market Insights, Epidemiology, and Market Forecast 2034' report provides a descriptive overview of the market access and reimbursement scenario of Adrenal Crisis.
This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.
Adrenal Crisis KOL Views
To keep up with current Adrenal Crisis market trends and fill gaps in secondary findings, we interview KOLs and SMEs working in the Adrenal Crisis domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or Adrenal Crisis market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the Adrenal Crisis unmet needs.
Adrenal Crisis: KOL Insights
DelveInsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as the Boston Children's Hospital in the US, CIBER de Enfermedades Cardiovasculares (CIBERCV) in Spain, Oita University, Yufu in Japan, University Children's Hospital, Magdeburg, in Germany, and organizations like Adrenal Crisis Research Foundation, International Adrenal Crisis Registry, among others.
"Adrenal crisis can be life-threatening. It is important to educate patients about proper medication and dosage importance."
Competitive Intelligence Analysis
We conduct a Competitive and Market Intelligence analysis of the Adrenal Crisis Market, utilizing various Competitive Intelligence tools such as SWOT analysis, Conjoint Analysis, and Market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.
The emerging Adrenal Crisis therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the Adrenal Crisis market.
Adrenal Crisis Pipeline Development Activities
The Adrenal Crisis market report offers an analysis of therapeutic candidates in Phase II and III stages and examines companies involved in developing targeted therapeutics for Adrenal Crisis. It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.
Pipeline Development Activities
The Adrenal Crisis market report covers information on collaborations, acquisition and merger, licensing, patent details, and other information for emerging Adrenal Crisis therapies.
The list will be continued in the report
The list will be continued in the report